Click on headlines below to download research
Termination of coverage
Termination of coverage | 30/11/2021
Edison Investment Research is terminating coverage on FinLab (A7A), The Scottish Investment Trust (SCIN), and Telix Pharmaceuticals (TLX). Please note…
Continued focus on its existing portfolio
FinLab | 14/10/2021
FinLab reported an NAV total return of 18% in H121, backed by the strong share price performance of its only listed holding Heliad Equity Partners (HEP)…
Benefiting from its fintech focus
FinLab | 30/03/2021
FinLab delivered a NAV total return of c 18% in FY20, primarily assisted by the share price of Heliad Equity Partners (HEP), in which FinLab holds a c…
Positive catalysts at portfolio holdings
FinLab | 07/10/2020
FinLab posted a strong NAV total return in H120 (+9.5%), driven by the solid share price performance of its only listed holding, Heliad Equity Partners…
Positive catalysts at portfolio holdings
FinLab | 25/09/2020
FinLab posted a strong NAV total return in H120 (+9.5%), driven by the solid share price performance of its only listed holding, Heliad Equity Partners…
Focus on existing holdings and EOS VC Fund
FinLab | 03/08/2020
FinLab has recently continued to focus on adding value to its existing fintech investments and expanding its portfolio of blockchain projects through the…
Seizing opportunities, ready for challenges
FinLab | 09/04/2020
FinLab’s recent focus was on existing portfolio holdings and selective investments in blockchain projects through the EOS VC Fund. Although some…
Executive interview
Executive interview - Finlab at EKF 2019 | 09/12/2019
In this interview, board member, Stefan Schutze, summarises FinLab's business model and portfolio. He discussed FinLab's recent round of funding by Deposit…
Adding value to the fintech portfolio
FinLab | 11/11/2019
Following the high transaction activity in H218, FinLab has since focused on value creation within its existing fintech portfolio companies. In H119, a…